Drug Trial Radar · NCT07600021
A Phase II Study to Evaluate the Efficacy and Safety of SYH2059 Tablets in Adult Patients With Idiopathic Pulmonary Fibrosis
Last checked: Nov 20, 2026Latest source record: May 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
156
Planned (sponsor's estimate)
Start
Jun 30, 2026
Primary completion
Oct 30, 2027
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- InnovStone Therapeutics LimitedIndustry
- Sponsor type
- Industry
- First posted
- May 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled Phase II study. It Aims aims to evaluate the efficacy and safety of different doses of SYH2059 tablets compared with placebo in adult patients with IPF, observe the PK profile of SYH2059 tablets in adult IPF patients, and assess the population pharmacokinetic (PPK) profile, exposure-response (E-R) relationship, as well as the changing trends of blood biomarkers.
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
SYH2059 TabletsDrug
Take twice daily, about 12 hours apart, after meals, for 12 weeks.
PlaceboDrug
Take twice daily, about 12 hours apart, after meals, for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in FVC from baseline (mL)Time frame: Week 12
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.